132 related articles for article (PubMed ID: 21296871)
21. Genome-wide bioinformatics analysis reveals CTCFL is upregulated in high-grade epithelial ovarian cancer.
Gong M; Yan C; Jiang Y; Meng H; Feng M; Cheng W
Oncol Lett; 2019 Oct; 18(4):4030-4039. PubMed ID: 31516605
[TBL] [Abstract][Full Text] [Related]
22. Tales from topographic oceans: topologically associated domains and cancer.
Campbell MJ
Endocr Relat Cancer; 2019 Nov; 26(11):R611-R626. PubMed ID: 31505466
[TBL] [Abstract][Full Text] [Related]
23. The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer.
Salgado-Albarrán M; González-Barrios R; Guerra-Calderas L; Alcaraz N; Estefanía Sánchez-Correa T; Castro-Hernández C; Sánchez-Pérez Y; Aréchaga-Ocampo E; García-Carrancá A; Cantú de León D; Herrera LA; Baumbach J; Soto-Reyes E
Oncogenesis; 2019 Aug; 8(8):41. PubMed ID: 31406110
[TBL] [Abstract][Full Text] [Related]
24.
Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic activation of POTE genes in ovarian cancer.
Sharma A; Albahrani M; Zhang W; Kufel CN; James SR; Odunsi K; Klinkebiel D; Karpf AR
Epigenetics; 2019 Feb; 14(2):185-197. PubMed ID: 30764732
[TBL] [Abstract][Full Text] [Related]
26. Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets.
Xie K; Fu C; Wang S; Xu H; Liu S; Shao Y; Gong Z; Wu X; Xu B; Han J; Xu J; Xu P; Jia X; Wu J
J Ovarian Res; 2019 Jan; 12(1):1. PubMed ID: 30609934
[TBL] [Abstract][Full Text] [Related]
27. Identification of potential prognostic TF-associated lncRNAs for predicting survival in ovarian cancer.
Guo Q; He Y; Sun L; Kong C; Cheng Y; Wang P; Zhang G
J Cell Mol Med; 2019 Mar; 23(3):1840-1851. PubMed ID: 30549251
[TBL] [Abstract][Full Text] [Related]
28. Expression of the POTE gene family in human ovarian cancer.
Barger CJ; Zhang W; Sharma A; Chee L; James SR; Kufel CN; Miller A; Meza J; Drapkin R; Odunsi K; Klinkebiel D; Karpf AR
Sci Rep; 2018 Nov; 8(1):17136. PubMed ID: 30459449
[TBL] [Abstract][Full Text] [Related]
29. BORIS: a key regulator of cancer stemness.
Soltanian S; Dehghani H
Cancer Cell Int; 2018; 18():154. PubMed ID: 30323717
[TBL] [Abstract][Full Text] [Related]
30. The prognostic role of BORIS and SOCS3 in human hepatocellular carcinoma.
Zhao R; Chen K; Zhou J; He J; Liu J; Guan P; Li B; Qin Y
Medicine (Baltimore); 2017 Mar; 96(12):e6420. PubMed ID: 28328845
[TBL] [Abstract][Full Text] [Related]
31. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
[TBL] [Abstract][Full Text] [Related]
32. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
[TBL] [Abstract][Full Text] [Related]
33. Combining Epigenetic and Immunotherapy to Combat Cancer.
Chiappinelli KB; Zahnow CA; Ahuja N; Baylin SB
Cancer Res; 2016 Apr; 76(7):1683-9. PubMed ID: 26988985
[TBL] [Abstract][Full Text] [Related]
34. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Blagitko-Dorfs N; Ford LA; Naqash R; Lübbert M; Karpf AR; Nemeth MJ; Griffiths EA
Oncotarget; 2016 Mar; 7(11):12840-56. PubMed ID: 26883197
[TBL] [Abstract][Full Text] [Related]
35. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
[TBL] [Abstract][Full Text] [Related]
36. A Common Polymorphism within the IGF2 Imprinting Control Region Is Associated with Parent of Origin Specific Effects in Infantile Hemangiomas.
Schultz B; Yao X; Deng Y; Waner M; Spock C; Tom L; Persing J; Narayan D
PLoS One; 2015; 10(10):e0113168. PubMed ID: 26496499
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical Study of Expression of Sohlh1 and Sohlh2 in Normal Adult Human Tissues.
Zhang X; Liu R; Su Z; Zhang Y; Zhang W; Liu X; Wang F; Guo Y; Li C; Hao J
PLoS One; 2015; 10(9):e0137431. PubMed ID: 26375665
[TBL] [Abstract][Full Text] [Related]
38. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
39. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
40. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
